NCNA
NuCana PLC
NASDAQ: NCNA · HEALTHCARE · BIOTECHNOLOGY
$2.13
+4.41% today
Updated 2026-04-30
Market cap
$9.20M
P/E ratio
0.00
P/S ratio
—
EPS (TTM)
$0.00
Dividend yield
—
52W range
$1 – $250
Volume
0.0M
NuCana PLC (NCNA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+50.3%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+100.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-10.0%
Last 1 reports
Positive reaction rate
0%
0 of 1 quarters
Largest single-day move
-10.0%
2025-11-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2025-11-13 | $-0.08 | +99.4% | $3.79 | $3.41 | -10.0% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-09-30 | $-13.00 | $-0.08 | +99.4% | — | — |
| 2025-06-30 | $-13.00 | $-23.31 | -79.3% | — | — |
| 2025-03-31 | $-13.00 | $-0.51 | +96.1% | — | — |
| 2024-12-31 | $-440.00 | $-64.85 | +85.3% | — | — |
| 2024-09-30 | $-790.00 | $-439.60 | +44.4% | — | — |
| 2024-06-30 | $-180.85 | $-300.00 | -65.9% | — | — |
| 2024-03-31 | $-276.55 | $-3.25 | +98.8% | — | — |
| 2023-12-31 | $-254.95 | $-350.00 | -37.3% | — | — |
| 2023-09-30 | $-10.07 | $-13.00 | -29.1% | — | — |
| 2023-06-30 | $-12.79 | $-10.00 | +21.8% | — | — |
| 2023-03-31 | $-11.00 | $-15.00 | -36.4% | — | — |
| 2022-12-31 | $-0.00 | $-0.00 | +0.0% | — | — |
Frequently asked questions
Has NuCana PLC beaten earnings estimates?
NuCana PLC has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +50.3% over the last 4 quarters.
How does NCNA stock react to earnings?
NCNA stock has moved an average of -10.0% in the trading day following earnings over its last 1 reports, with positive reactions in 0% of those quarters.